MSN: The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'
Sarepta stock plunged again Thursday on a report that the Food and Drug Administration will require additional clinical testing to validate the safety profile of its controversial gene therapy, ...
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'
In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular dystrophy (DMD) treatment ELEVIDYS. The patient passed away due to acute ...
FiercePharma: Sarepta pushes for full approval of Duchenne drugs despite missed confirmatory trial goal
A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal. The development comes just as the company and the FDA work to formally ...
Sarepta pushes for full approval of Duchenne drugs despite missed confirmatory trial goal
Seeking Alpha: Sarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian Play
Sarepta Therapeutics, Inc. faces a disastrous 2025, with Elevidys-linked patient deaths, halted shipments, and a >90% stock price collapse. SRPT implemented a major restructuring, slashing 36% of its ...
Sarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian Play
Sarepta Therapeutics is trading around $19 in extended hours following the FDA’s decision to remove the pause on Elevidys, marking a critical turning point for the beleaguered biotech. This regulatory ...
FILE PHOTO: A sign marks the offices of Sarepta Therapeutics in Cambridge, Massachusetts, U.S., . REUTERS/Brian Snyder/File Photo (Reuters) -Sarepta Therapeutics' shares plunged nearly 40 ...